Tuesday, October 6, 2026
← Back to archivePolicy
Policy•STAT News•Oct 6, 2026
Opinion: Why the FDA should not approve an ineffective multicancer screening test
background ▾
- •Grail's FDA-recommended multicancer screening test failed its primary endpoint in a 140,000-person trial but used late-stage cancer detection (surrogate) rather than cancer mortality (gold standard), a methodological flaw that undermines clinical validity for a screening indication.
- •The Medicare Multi-Cancer Early Detection Screening Coverage Act creates automatic Medicare coverage, potentially forcing taxpayer funding of an unproven screening test—a critical policy-regulatory misalignment with evidence standards applied to breast, colorectal, lung, and prostate cancer screening.
- •Watch for: final FDA decision on Grail's approval, congressional scrutiny of the coverage mandate, resolution of investor litigation, and whether other multicancer blood test developers (including Illumina-backed competitors) face similar evidentiary standards or regulatory pathway expeditions.
GrailIlluminaGALLERI
→ Read original articlePolicy•KFF•Oct 6, 2026
AI: Does Europe Have the Answer?
background ▾
- •Europe has chosen a regulatory pathway for AI with strict rules rather than a development pause, contrasting with ongoing U.S. policy debate
Policy•KFF•Oct 6, 2026
Current and Historical Public Opinion on Medicare-for-All and Other National Health Plan Proposals
background ▾
- •Medicare-for-all support reached 66% in September 2026—a new historical high and 13 percentage points above 2020 levels—signaling growing public appetite for healthcare system transformation that could fundamentally alter pharma pricing and reimbursement landscape.
- •Republican support for Medicare-for-all doubled from 21% (2020) to 34% (2026), indicating potential bipartisan feasibility for healthcare reform that was previously considered politically intractable.
- •Watch for Democratic midterm campaign outcomes and whether Medicare-for-all gains legislative traction post-2026 elections, as single-payer implementation could trigger CMS rate-setting authority, price controls, and consolidated drug procurement mechanisms that would restructure pharma commercial models.
Policy•STAT News•Oct 6, 2026
In this hospital, pulse oximeters went from overestimating to underestimating blood oxygen. Why?
background ▾
- •Pulse oximeters show inconsistent behavior year-to-year at the same institution, shifting from overestimation to underestimation, making clinical adjustment strategies unreliable and exacerbating health equity concerns.
- •The root cause remains unexplained despite manufacturer (Masimo) denial of sensor, software, or manufacturing changes, indicating a potential gap in device traceability and quality control monitoring.
- •Clinicians and regulators must determine whether pulse oximeter accuracy can be reliably standardized or whether alternatives to these widely-used devices should be prioritized in clinical protocols, particularly for vulnerable populations.
MasimoPulse oximeters
→ Read original articlePolicy•KFF•Oct 5, 2026
Is This A Healthcare Economy?
background ▾
- •Healthcare sector employment growth (2%) vastly exceeded non-healthcare economy growth (0.1%) in the past year, driven by aging populations and chronic disease burden
Market Access
Market Access•Fierce Biotech•Oct 5, 2026
Meet Motivista: Click Therapeutics debuts first-of-its-kind schizophrenia digital therapeutic
background ▾
- •First FDA-cleared treatment specifically for negative schizophrenia symptoms, addressing a significant unmet medical need where current antipsychotics focus only on positive symptoms
- •Commercial strategy is entirely contingent on state Medicaid coverage decisions; Click will deploy resources only in states with established access rather than pursuing nationwide launch
- •No pricing announced pending Medicaid negotiations; the company acknowledges that out-of-pocket models would exclude most schizophrenia patients who rely on Medicaid
Click TherapeuticsBoehringer IngelheimMotivistaCT-155
→ Read original articleMarket Access•Fierce Biotech•Oct 5, 2026
How to Choose a Biologics CDMO: 4 Criteria That Matter the Most
background ▾
- •Quality and regulatory compliance (GMP deviations, FDA Form 483s, inspection history) remain the baseline buying factor for CDMO selection, but price competitiveness has risen sharply in importance (from 7th to 2nd ranking).
- •European CDMOs are capturing significantly more FDA-approved manufacturing deals than US-based partners due to cost advantages, reflecting industry consolidation pressures on manufacturing economics.
Rezon Bio
→ Read original articleMarket Access•STAT News•Oct 6, 2026
Opinion: I’m a doctor. Here’s what I want the public to know about AI tools and health care costs
background ▾
- •Blue Cross Blue Shield research documented that hospitals using AI-assisted documentation tools to identify and code secondary diagnoses have inflated insurer costs by hundreds of millions over two years through 'bump codes' that enable higher DRG-based billing without additional clinical intervention.
- •AI-powered clinical documentation integrity (CDI) tools systematically prompt physicians to document secondary findings (anemia, malnutrition, low sodium) detected in labs, creating financial incentives that may divorce documentation from actual clinical treatment priorities.
- •The scalability of automated diagnosis detection combined with DRG reimbursement structure creates a systemic vulnerability; addressing this requires either policy reform to DRG methodology or institutional guardrails on documentation tool design and deployment.
Blue Cross Blue Shield
→ Read original articleMarket Access•Fierce Biotech•Oct 6, 2026
AstraZeneca hopes to ‘achieve amazing things’ with new Kendall Square R&D center
background ▾
- •AstraZeneca is significantly expanding its Massachusetts R&D footprint with a 2,000-person center employing AI-integrated laboratory infrastructure, signaling confidence in the Boston ecosystem for drug discovery
AstraZenecaBroad InstituteThermo Fisher Scientific
→ Read original articleMarket Access•Fierce Biotech•Oct 6, 2026
TRex Bio stomps toward $111M IPO, as Retension and Lycia also gear up to go public
background ▾
- •TRex Bio's $111.3M IPO is anchored by a Lilly option deal and phase 1 data in atopic dermatitis expected mid-2027, with Lilly confirming interest in participation.
- •Retension's $33.8M IPO funds phase 2b/3 trials of RTN-001, a next-gen PDE-5 inhibitor engineered to overcome cardiovascular limitations of first-generation agents in hypertension.
- •Watch for TRex's mid-2027 phase 1 AD readout and Retension's phase 2b hypertension data, which will validate clinical feasibility and differentiation claims ahead of larger late-stage programs.
TRex BioEli LillyJohnson & JohnsonTRB-061TRB-071RTN-001
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Oct 5, 2026
Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots
background ▾
- •VAX-31 achieved non-inferiority on all 20 Prevnar 20 serotypes and 17 of 19 Capvaxive serotypes, with only serotypes 3 and 12F narrowly missing the primary threshold but still meeting a historical lower bound, representing a significant competitive positioning in a crowded pneumococcal vaccine market.
- •The company's carrier-sparing conjugation technology successfully preserved antibody responses across 31 serotypes without the typical immunogenicity penalty seen in higher-valent vaccines, validating the proprietary platform's technical differentiation.
- •Watch for H1 2025 readouts from Opus-2 and Opus-3 trials plus phase 2 pediatric data; FDA approval decision in H1 2028 will hinge critically on comparative performance against Capvaxive serotypes 3 and 12F, which account for a substantial share of US pneumococcal disease burden.
VaxcytePfizerMerck & Co.VAX-31Prevnar 20Capvaxive
→ Read original articleClinical Trials•Endpoints News•Oct 5, 2026
Genmab details ovarian cancer data; Lilly's Jaypirca gets a label expansion
background ▾
- •Genmab's Rina-S demonstrated a 45.9% response rate in ovarian cancer, supporting the clinical utility of FRα-directed ADC approach in this indication
- •Eli Lilly achieved label expansion for Jaypirca, indicating progression of this asset in its commercial lifecycle
GenmabEli LillyBiogenRina-SJaypirca
→ Read original article